Can hydralazine tablets be split in half?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Hydralazine Tablets Be Split in Half?

Yes, hydralazine tablets can generally be split in half, though this practice comes with important caveats regarding dose uniformity and patient capability.

Key Considerations for Splitting Hydralazine

Tablet Formulation Compatibility

Hydralazine is available as immediate-release tablets (10 mg, 25 mg, 50 mg, 100 mg) that are not extended-release formulations 1. Since hydralazine is not a sustained-release preparation, splitting does not risk the dangerous alteration of drug release kinetics that occurs with extended-release medications 2, 3. This makes hydralazine theoretically safer to split than many other cardiovascular medications.

Dose Uniformity Concerns

The evidence on tablet splitting reveals significant concerns about achieving uniform doses:

  • Weight and content variability: Research demonstrates that many commonly split tablets fail USP uniformity standards, with 15-16% of half tablets falling outside acceptable specifications 4
  • Fragment loss: Tablets may lose 1-2% of their mass during splitting due to powdering, though this is generally minimal for most medications 4
  • Splitting method matters: Hand-splitting produces worse uniformity than using a razor blade or tablet splitter 5

Clinical Context for Hydralazine

Hydralazine has pharmacological properties that make splitting more acceptable:

  • Wide therapeutic index: Hydralazine does not have the narrow therapeutic window of drugs like digoxin or warfarin
  • Long duration of action: Effects last 2-4 hours after IV administration 6, 7, suggesting some tolerance for dose variability
  • Flexible dosing: FDA labeling shows hydralazine is initiated at 10 mg four times daily and titrated up to 50 mg four times daily, with doses ranging from 40-300 mg daily 1, indicating the drug tolerates dose adjustments

Practical Recommendations

When splitting is appropriate:

  • Use a tablet splitter device rather than hand-breaking or knife-cutting to maximize uniformity 2, 5
  • Consider splitting only for dose titration or cost savings when clinically appropriate
  • Ensure the patient has the physical capability and cognitive ability to split tablets accurately 8
  • Avoid splitting for elderly patients with dexterity limitations who may struggle with the mechanical task 2, 8

When to avoid splitting:

  • Patients requiring precise dosing for critical blood pressure control
  • Individuals unable to use a tablet splitter properly
  • When pre-manufactured lower-strength tablets are available and affordable

Important Caveats

The FDA labeling for hydralazine does not specifically address tablet splitting 1. The tablets are described as "round, peach core tablet" without mention of scoring, which typically indicates the manufacturer has not validated the product for splitting 1. However, the absence of extended-release properties and the drug's pharmacological characteristics make splitting less hazardous than for many other medications.

Storage after splitting: Split tablets should be dispensed in "tight, light-resistant containers" as hydralazine requires protection from light 1. Split tablets should be used promptly rather than stored long-term.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.